Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Trulieve Cannabis (TCNNF) Cash & Equivalents (2020 - 2025)

Trulieve Cannabis (TCNNF) has 6 years of Cash & Equivalents data on record, last reported at $255.5 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 7.01% year-over-year to $255.5 million; the TTM value through Dec 2025 reached $255.5 million, up 7.01%, while the annual FY2025 figure was $255.5 million, 7.01% up from the prior year.
  • Cash & Equivalents reached $255.5 million in Q4 2025 per TCNNF's latest filing, down from $449.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $449.2 million in Q3 2025 and bottomed at $100.7 million in Q3 2022.
  • Average Cash & Equivalents over 5 years is $247.1 million, with a median of $232.1 million recorded in 2021.
  • Peak YoY movement for Cash & Equivalents: plummeted 52.87% in 2022, then surged 133.11% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $226.6 million in 2021, then dropped by 8.58% to $207.2 million in 2022, then fell by 2.81% to $201.4 million in 2023, then grew by 18.59% to $238.8 million in 2024, then rose by 7.01% to $255.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $255.5 million in Q4 2025, $449.2 million in Q3 2025, and $392.6 million in Q2 2025.